#1 Clinical Trials Search in Europe

TETANUS TOXOID

Tetanus Toxoid (TT) is a crucial component in preventing tetanus, a serious disease caused by bacteria that can lead to muscle stiffness and spasms. Clinical trials involving Tetanus Toxoid are important for understanding how this vaccine works, especially when combined with other treatments like Tetanus Immune Globulin (TIG). These studies help researchers determine the most effective ways to protect individuals who have either never been vaccinated against tetanus or whose antibody levels have fallen below protective thresholds. This article explores the research being conducted on Tetanus Toxoid, particularly focusing on how it functions when administered alongside other tetanus-preventing medications.

Table of Contents

What is Tetanus Toxoid?

Tetanus toxoid (TT) is a vaccine used to prevent tetanus, a serious bacterial infection that affects the nervous system and causes painful muscle contractions, particularly of the jaw and neck muscles. This condition is sometimes called “lockjaw.” Tetanus toxoid is a weakened form of the toxin produced by the tetanus bacteria (Clostridium tetani), which has been treated to remove its harmful effects while still stimulating the immune system to produce protective antibodies[1].

Tetanus toxoid is often administered as part of combination vaccines, such as the Diphtheria-Tetanus Toxoids Adsorbed (dT) vaccine, which protects against both tetanus and diphtheria[1].

How Tetanus Toxoid Works

When you receive a tetanus toxoid vaccine, your immune system recognizes the inactivated toxin and produces antibodies against it. These antibodies can then protect you if you’re ever exposed to the actual tetanus bacteria, for example, through a contaminated wound[1].

The protection provided by tetanus toxoid isn’t immediate. Your body needs time to build up sufficient antibody levels for protection. That’s why it’s important to stay up-to-date with recommended tetanus boosters, typically given every 10 years for adults[1].

Tetanus Immune Globulin (TIG)

Tetanus Immune Globulin (Human), also known as TIG, is different from tetanus toxoid. While tetanus toxoid is a vaccine that stimulates your body to produce its own antibodies, TIG contains ready-made antibodies against tetanus. These antibodies provide immediate, passive protection against tetanus infection[1].

TIG is typically used in specific situations, such as:

  • For people with wounds that might be contaminated with tetanus bacteria who haven’t completed their tetanus vaccination series
  • For individuals whose tetanus antibody levels are below protective levels
  • For people with no known history of tetanus immunization

TIG provides immediate but temporary protection. Its effectiveness begins to diminish after administration, which is why it’s often given together with tetanus toxoid to provide both immediate and long-term protection[1].

Combined Protection: Tetanus Toxoid and Tetanus Immune Globulin

Research has been conducted to evaluate the effectiveness of giving tetanus toxoid (in the form of dT vaccine) and Tetanus Immune Globulin (TIG) together. The World Health Organization (WHO) recommends this dual approach for individuals at risk of developing tetanus who have no immunization history or whose tetanus antibody levels are below protective levels[1].

When administered concurrently, these products work in complementary ways:

  • TIG provides immediate protection with ready-made antibodies
  • Tetanus toxoid stimulates the body to produce its own antibodies for longer-term protection

Studies have monitored the pharmacokinetic profile (how the body processes a substance over time) of antibody levels when TIG and tetanus toxoid are given together. These studies track important measurements such as:

  • Cmax – the maximum concentration of antibodies in the blood
  • Tmax – the time it takes to reach the maximum concentration
  • Duration of protective antibody levels

This research helps healthcare providers understand how long protection lasts and how best to administer these products for optimal patient safety[1].

Alternative Names for Tetanus Products

Tetanus Immune Globulin (Human) may be sold under several brand names, including:

  • HyperTET S/D
  • BayTet
  • BAY 19-8515
  • TAL-05-00013
  • NDC 13533-634-02

Your healthcare provider may refer to these products by any of these names, but they all contain tetanus immune globulin for immediate protection against tetanus[1].

Who Needs Tetanus Protection

Tetanus protection is particularly important for:

  • People with no known history of tetanus immunization
  • Individuals whose last tetanus-containing vaccine was received more than 10 years ago
  • People with wounds that might be contaminated with tetanus bacteria (especially deep puncture wounds, wounds with dead tissue, or wounds exposed to soil or manure)
  • Individuals whose tetanus antibody levels have been tested and found to be below protective levels

If you’re unsure about your tetanus immunization status, it’s important to discuss this with your healthcare provider, especially if you sustain a wound[1].

Monitoring Protection Levels

In clinical research settings, tetanus antibody levels can be measured in the blood to determine if a person has adequate protection against tetanus. These measurements help researchers understand:

  • How quickly protection develops after vaccination or TIG administration
  • How long protection lasts
  • When booster doses might be needed

In one study, researchers measured antibody levels on days 1, 2, 3, 4, 5, 7, 14, 21, 30, and 40 after administration of both dT and TIG to understand the complete profile of protection. This type of detailed monitoring helps develop evidence-based recommendations for tetanus prevention[1].

Aspect Details
Study Type Prospective, open-label, single-center clinical trial
Study Population 6 subjects with no known tetanus immunization history or >10 years since last tetanus vaccine
Interventions Concurrent administration of Tetanus Immune Globulin (TIG) and Diphtheria-Tetanus Toxoids Adsorbed (dT)
Study Duration 40 days of follow-up after administration
Primary Outcome Measurement of tetanus antibody titers at multiple time points (Days 1, 2, 3, 4, 5, 7, 14, 21, 30, and 40)
Key Measurements Serum level vs. time curve, maximum concentration (Cmax), time to maximum concentration (Tmax), and duration of protective antibody levels
Clinical Significance May provide evidence supporting WHO recommendations for dual coverage with both passive (TIG) and active (TT) immunization for optimal tetanus protection
Drug Brand Names HyperTET S/D, BayTet (for Tetanus Immune Globulin)

FAQ

  • What is the purpose of the clinical trial studying Tetanus Toxoid? The clinical trial aims to re-evaluate how tetanus antibodies behave in the body (pharmacokinetic profile) when Tetanus Immune Globulin (TIG) and Tetanus Toxoid (TT) vaccine are given at the same time. The study specifically controls the anatomical location and timing of administration to understand how this combination provides protection against tetanus, potentially supporting World Health Organization (WHO) recommendations that dual coverage provides the best protection for people at risk of tetanus.
  • Who is eligible to participate in this Tetanus Toxoid clinical trial? The trial is designed for participants who either have no known history of tetanus immunization or whose last tetanus-containing vaccine was administered more than 10 years ago. This means their tetanus antibody levels would likely be below the protective threshold, making them appropriate candidates to study the effects of combined TIG and TT administration.
  • How is the clinical trial structured? This is a prospective, open-label, single-center trial with a single group of subjects. The study plans to enroll six participants who will receive both Diphtheria-Tetanus Toxoids Adsorbed (dT) and Tetanus Immune Globulin (TIG) at the same time on Day 1. Participants will then be followed for 40 days with antibody measurements taken on Days 1, 2, 3, 4, 5, 7, 14, 21, 30, and 40.
  • What data is being collected during the trial? The primary data being collected are tetanus antibody levels in the blood at various time points over 40 days. From these measurements, researchers will determine the serum level versus time curve, maximum concentration (Cmax), time to reach maximum concentration (Tmax), and how long protective antibody levels last. This information helps understand how the body responds to the combined administration of TIG and TT.
  • What medications are used in this Tetanus Toxoid clinical trial? The trial uses Tetanus Immune Globulin (Human), also known by brand names like HyperTET S/D and BayTet, along with Diphtheria-Tetanus Toxoids Adsorbed (dT). The TIG is administered according to package insert recommendations and WHO guidelines. These medications work together to provide both immediate (passive) immunity through TIG and longer-term (active) immunity through the tetanus toxoid component of the dT vaccine.

Ongoing Clinical Trials on TETANUS TOXOID

  • Study of B Cell Response to Tetanus Toxoid Vaccination in Patients with Systemic Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Best Timing for Pertussis Vaccination in Pregnant Women Using Diphtheria, Tetanus, and Pertussis Vaccine

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Belgium

  • Study of acellular pertussis vaccine and its effect on whooping cough colonization in healthy adults using controlled human infection

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of dTap Vaccine in Boosting Immunity Against Diphtheria, Tetanus, and Whooping Cough in Healthcare Workers

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Finland

  • Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Finland Germany Hungary Spain

  • Study on How Vaccines Affect Infant Immunity to Whooping Cough in Babies Born to Vaccinated Mothers Using Diphtheria, Tetanus, and Pertussis Vaccine Combination

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium

  • Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

    Not recruiting

    1 1 1
    Investigated drugs:
    Czechia Denmark Finland Germany Poland Spain

Glossary

  • Tetanus Toxoid (TT): A vaccine made from the toxin produced by the tetanus bacteria (Clostridium tetani) that has been inactivated so it cannot cause disease but can still stimulate the immune system to produce protective antibodies against tetanus.
  • Tetanus Immune Globulin (TIG): A blood product that contains antibodies against tetanus. It provides immediate but temporary protection against tetanus infection, known as passive immunity. Brand names include HyperTET S/D and BayTet.
  • Pharmacokinetic profile: The study of how a drug or vaccine moves through the body over time, including how it's absorbed, distributed, metabolized, and eliminated. In this trial, it refers to tracking tetanus antibody levels in the blood over 40 days.
  • Antibody titer: A measurement of the amount or concentration of antibodies in the blood. Higher titers generally indicate stronger immune protection against a specific disease.
  • Protective levels: The minimum concentration of antibodies in the blood needed to provide effective protection against a disease. Levels below this threshold indicate vulnerability to infection.
  • Cmax: The maximum concentration of a substance (in this case, tetanus antibodies) reached in the blood after administration of a drug or vaccine.
  • Tmax: The time it takes to reach the maximum concentration (Cmax) of a substance in the blood after administration.
  • Passive immunization: Providing ready-made antibodies (through products like TIG) to give immediate, short-term protection against an infection. The protection wears off as the antibodies naturally break down.
  • Active immunization: Stimulating the body's own immune system to produce antibodies against a disease, usually through vaccination (like Tetanus Toxoid). This provides longer-lasting protection.
  • Diphtheria-Tetanus Toxoids Adsorbed (dT): A combination vaccine that protects against both diphtheria and tetanus. The 'adsorbed' part means the vaccine components are attached to an adjuvant (usually aluminum salt) to enhance the immune response.
  • Open-label trial: A type of clinical trial where both the researchers and participants know which treatment is being administered, as opposed to a blinded study where this information is hidden.
  • Prospective trial: A study that follows participants forward in time to observe outcomes after an intervention, rather than looking back at past data.

References

  1. https://clinicaltrials.gov/study/NCT00437671